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Objectives: To investigate the efficacy of progestin treatment to achieve pathological 24 
complete response (pCR) in patients with complex atypical endometrial hyperplasia (CAH) 25 
or early endometrial adenocarcinoma (EC). 26 
Methods: A systematic search identified 3245 potentially relevant citations. Studies 27 
containing less than ten eligible CAH or EC patients in either oral or intrauterine treatment 28 
arm were excluded. Only information from patients receiving six or more months of 29 
treatment and not receiving other treatments was included. Weighted proportions of patients 30 
achieving pCR were calculated using R software. 31 
Results: Twelve studies met the selection criteria. Eleven studies reported treatment of 32 
patients with oral (219 patients, 117 with CAH, 102 with grade 1 Stage I EC) and one 33 
reported treatment of patients with intrauterine progestin (11 patients with grade 1 Stage 34 
IEC). Overall, 74% (95% confidence interval [CI] 65-81%) of patients with CAH and 72% 35 
(95% CI 62-80%) of patients with grade 1 Stage I EC achieved a pCR to oral progestin. 36 
Disease progression while on oral treatment was reported for 6/219 (2.7%), and relapse after 37 
initial complete response for 32/159 (20.1%) patients. The weighted mean pCR rate of 38 
patients with grade 1 Stage I EC treated with intrauterine progestin from one prospective pilot 39 
study and an unpublished retrospective case series from the Queensland Centre of 40 
Gynaecologic Oncology (QCGC) was 68% (95% CI 45- 86%). 41 
Conclusions: There is a lack of high quality evidence for the efficacy of progestin in CAH or 42 
EC. The available evidence however suggests that treatment with oral or intrauterine 43 
progestin is similarly effective. The risk of progression during treatment is small but longer 44 
follow-up is required. Evidence from prospective controlled clinical trials is warranted to 45 
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Endometrial cancer is the most common gynaecological cancer in developed countries, with 56 
an estimated incidence per year of 23.5 per 100,000 in the US [1], 18.5 per 100,000 in 57 
Canada [2] and 16.5 per 100,000 in Australia [3]. In patients younger than 50 years of age the 58 
incidence of endometrial cancer is increasing by 1% per year [1].  59 
Overall, 84% of all endometrial cancers are Type 1 endometrioid adenocarcinomas (EC) [4], 60 
which typically carry a good prognosis. Type 1 EC is associated with obesity, diabetes 61 
mellitus and hypertension. Increasing body mass index has been shown to be strongly 62 
associated with the development of EC[5-7]. It has been estimated that at least 16,000 new 63 
cases of EC in Europe in 2002 were caused by obesity (population attributable risk of 30.0; 64 
95% CI 25.6 – 34.4) [8].  65 
Complex atypical endometrial hyperplasia (CAH), a precursor lesion of EC, is also more 66 
common in obese patients, and is estimated to progress to EC in 15-75% of patients [9-16]. 67 
Invasive EC can already be found in approximately 30% of patients initially diagnosed with 68 
CAH [17]. 69 
The current standard treatment for CAH and endometrial cancer is hysterectomy and bilateral 70 
salpingo-oophorectomy [18-21] with or without surgical staging [22]. While radical surgery 71 
offers good 5-year survival prospects of 75-90% [20], it also eliminates prospects of further 72 
fertility. Many patients carry a high burden of medical co-morbidities, which has been 73 
associated with a higher risk of surgical adverse events [23-26]. For example, wound 74 
infections are a frequent postoperative complication in obese patients [24]. 75 
It is thus accepted clinical practice to offer oral and/or intrauterine-delivered (IUD) progestin 76 
to selected patients diagnosed with CAH and EC. In particular, two groups of patients might 77 
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benefit most: a) young women diagnosed with CAH and EC who still wish to have children 78 
and b) patients with severe medical co-morbidities precluding (immediate) surgery [27-42].  79 
No evidence from randomised controlled trials is available and no randomised controlled 80 
trials are currently underway on the efficacy of progestin treatment in achieving a 81 
pathological complete response. Although there are a number of previous, mostly small, 82 
systematic reviews or meta-analyses reporting outcomes of progestin therapy, none of these 83 
reviews restricted outcomes to pathological complete response, posed restrictions on the 84 
duration of treatment or detailed the response to either oral or intrauterine progestin 85 




A systematic review was conducted to identify all articles published between January 1950 90 
and February 2011 involving patients with CAH or grade 1, clinical Stage I EC treated with 91 
intrauterine or oral progestins. Systematic searches were performed using MEDLINE, 92 
Cochrane Library, ScienceDirect, DynaMed and MD Consult Australia. Database selection 93 
and search terms for use were formulated with the guidance of a subject librarian with 94 
expertise in the field. A combination of Medical Subject Headings (MeSH) and keyword 95 
searches were used. The number of search terms used was dependent on the number of terms 96 
allowed by each database. MEDLINE, which allowed the most tailored and extensive search, 97 
was used to generate two subsets of citations, for relevant participant and intervention type, 98 
which were combined with “AND”. Searches were limited to English literature and human 99 
studies. The keywords “endometrial”, “uterine”, “adenocarcinoma”, “carcinoma”, “cancer”, 100 
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“neoplasm” or MeSH term “Endometrial Hyperplasia” were used for participant type and 101 
“progestin”, “progestogen”, “progestagen”, “progesterone”, “gestogen”, “levonorgestrel”, 102 
“levonogestrel”, “medroxyprogesterone”, “megestrol”, “noresthisterone”, “dydrogesterone”, 103 
“ethisterone”, or “norgestrel” for intervention type. Keyword searches were performed on 104 
ScienceDirect and Cochrane Library using the terms “endometrial AND proges*”. The topics 105 
“Endometrial Cancer” and “Endometrial Hyperplasia” were searched for relevant papers in 106 
DynaMed and MD Consult Australia. Reference lists of primary and review articles were 107 
scanned for other relevant studies not identified through electronic searches. 108 
Selection of studies 109 
Pre-defined inclusion and exclusion criteria for study selection were established prior to 110 
conducting the literature search. We included cohort studies, case series, comparative studies, 111 
controlled studies, and prospective studies, involving ten or more CAH patients receiving any 112 
single route of administration or ten or more EC patients receiving any single route of 113 
administration (either oral or IUD progestin treatment) and reporting pathological complete 114 
response rate as the primary outcome. Patients were eligible if aged eighteen years or older 115 
and treated for six months or longer with oral or intrauterine progestin and had pretreatment 116 
computed tomography or magnetic resonance imaging to confirm staging for EC patients. 117 
However, we decided to include one study where 6 of the 11 patients selected for review only 118 
had a transvaginal ultrasonography due to not being able to fit into MRI because of body 119 
habitus. This study was included as it was the only study available with 10 or more patients 120 
with EC treated with progestin by IUD [46].  We excluded studies that treated patients with 121 
progestin and simultaneously with additional treatment such as hysteroscopic ablation, 122 
radiotherapy, chemotherapy, other endocrine treatment (tamoxifen, bromocriptine), or other 123 
routes of administration of progestins (intramuscular, transdermal, vaginal). 124 
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A two-stage process was used to select relevant studies for the review (Figure 1). Two 125 
authors (J.B. and M.J.) independently examined titles and abstracts of all articles identified 126 
through electronic searches and excluded those not meeting the selection criteria. The second 127 
stage involved examination of full manuscripts and final decisions about inclusion and 128 
exclusion of studies. Where more than one article was found describing the same study, only 129 
the most recent or most complete publication was included. Full manuscripts were also 130 
obtained of review articles to allow identification of potentially eligible studies from 131 
reference lists. 132 
Data extraction 133 
Data extraction was performed by one author (J.B.) and entered into a predesigned 134 
spreadsheet. Where studies contained both patients that did and did not meet inclusion criteria 135 
but allowed distinction of outcomes, only information about patients fulfilling selection 136 
criteria was extracted. For studies where ambiguity existed about outcomes for a subset of 137 
participants fulfilling our criteria, authors were contacted with requests for clarification. 138 
For each selected study, information was extracted about study design and number of patients 139 
treated for CAH or EC. We also summarised patients’ mean age and age range, study setting 140 
and country, study period, actual and intended follow-up, dropout rates for prospective 141 
studies, route of progestin treatment, treatment duration, drug, dose and regimen, and rates of 142 
complete and partial pathological response, relapse, progression, pregnancies and live births. 143 
Fertility outcomes were only extracted from studies included in our analysis. 144 
From our centre database (Queensland Centre of Gynaecological Cancer Series 2004-2011) 145 
we retrospectively extracted all patients with histological grade 1 and apparent Stage I EC 146 
based on CT scan of pelvis and abdomen and either a chest X-ray or CT scan of the chest, 147 
who were treated with a Mirena levonorgestrel-releasing intrauterine device (IUD) for at least 148 
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six months. Overall, eleven patients were identified, and data on pathological complete 149 
response, or evidence of persistent disease or progression was extracted. 150 
Outcome measure 151 
Our primary outcome measure of interest was pathological complete response, defined as 152 
histological regression to normal endometrium, including proliferative, secretory, inactive or 153 
atrophic endometrium. Histological regression to simple or complex endometrial hyperplasia 154 
without atypia was classified as a partial pathological response. Worsening of CAH to EC on 155 
histology or of grade 1 Stage I EC to a higher grade or stage on histology or surgical staging 156 
was classified as progression. 157 
Statistical analyses 158 
Using SAS software, for each study, the proportion of patients achieving pathological 159 
complete response with exact binomial 95% confidence intervals was computed [47]. Across 160 
studies, weighted proportions were then calculated, producing a pooled overall estimate and 161 
95% confidence intervals. Chi-squared tests were used to assess statistical heterogeneity.  162 
Forest plots of sample size against proportion achieving pathological complete response were 163 
produced using R software and examined for publication bias. 164 
To assess the effect of the inclusion criteria applied in the main analyses, two sensitivity 165 
analyses were conducted. We compared the pathological complete response rate obtained 166 
from the main analysis against: 167 
Expanded analysis: Pathological complete response rate obtained when inclusion criteria 168 
were widened to include studies with three or more eligible CAH or EC patients in either 169 





The electronic search strategy yielded a total of 3245 potentially relevant citations after 173 
removal of duplicates. The agreement between independent reviewers was 98% for selection 174 
of full manuscripts to be examined (Cohen’s Kappa 0.65) and 100% for studies to be 175 
included. Overall, 3139 citations were excluded on the basis of title and abstract information 176 
(Figure 1). Examination of reference lists of review articles identified a further ten studies of 177 
potential relevance. Full manuscripts were thus obtained and examined for 116 articles, and 178 
12 studies met selection criteria, of which 11 involved oral progestin treatment (6 179 
retrospective case series, 2 prospective case series, 1 prospective cohort, 1 retrospective 180 
cohort, and 1 retrospective comparative study). In addition, weighted mean response rates for 181 
patients with grade 1 Stage I EC to intrauterine progestin treatment was estimated from one 182 
prospective pilot study by Montz and colleagues (11 patients) [46] and from our retrospective 183 
case series conducted at QCGC (11 patients). Four studies not previously included in reviews 184 
were identified [15, 28, 29, 39]. Characteristics of included studies are described in Table 1. 185 
Oral Progestins: Meta-analysis of studies of oral progestin treatment involved a total of 219 186 
patients, 117 with CAH and 102 with grade 1 Stage I EC; patients’ age ranged from 19 to 77 187 
years (mean age 36 years from nine studies that reported age for patients extracted for this 188 
meta-analysis, median value used for study by Hahn et al.). Follow-up ranged from 6 months 189 
to 23 years, with mean value of 45.8 months (median value used for study by Hahn et al.). 190 
The majority of patients (153/219, 70%) were treated with daily medroxyprogesterone acetate 191 
(MPA) 2.5–1500mg/day; 34/219 (15.5%) were treated with daily megestrol acetate 80–192 
320mg/day; 12/219 (5.5%) were treated with cyclic MPA 10mg/day for 14 days of each 193 
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menstrual cycle, and 8/219 (4%) were treated with both MPA and megestrol. One study did 194 
not specify type of progestin used [48]. 195 
Overall, 86/117 (74%, 95% CI 65–81%) of patients with CAH and 73/102 (72%, 95% CI 66–196 
78%) of patients with grade 1 Stage I EC achieved a pathological complete response with 197 
oral progestin treatment for six months or longer. Pathological complete response rates varied 198 
from 50-94% between CAH studies and 50-100% between EC studies. There was no 199 
evidence of heterogeneity between studies involving CAH patients (p=0.25), but 200 
heterogeneity was observed between studies involving EC patients (p=0.001).  201 
Time taken to achieve pathological complete response ranged from 1 to 12 months with a 202 
mean of 5.9 months among the four studies that reported this (median value used for study by 203 
Hahn et al.). In addition, 18/219 (8.2%) patients achieved partial remission (range: 0–30% 204 
between studies). Non-responders (36/219, 16%) were reported to have undergone 205 
hysterectomy in five studies [28, 29, 32, 33, 35] . 206 
Overall, 6/219 patients (2.7%) progressed from CAH to Stage I EC (grade 1 EC in five cases, 207 
grade 2 EC in one case) during oral progestin treatment. No patients with EC are reported to 208 
have progressed under treatment. Of the 159 patients who initially achieved a pathological 209 
complete response, 32/159 (20.1%) relapsed on longer follow-up. Reported relapse rates 210 
among responders varied from 0-50% between studies. Of 14 CAH patients who achieved 211 
pathological complete response and then relapsed, 8 had recurrence of CAH and 6 developed 212 
EC. Of 18 EC patients who achieved pathological complete response and then relapsed, 6 213 
developed CAH and 12 had recurrence of EC. Time until relapse ranged from 4 months to 7 214 
years after the completion of progestin treatment, with mean 27 months for seven studies that 215 
reported time until relapse (median value used for study by Hahn et al.). Six patients who 216 
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relapsed were reported to have been treated with a second course of oral progestin, of which 217 
three successfully achieved pathological complete response. 218 
Of the nine studies that reported on fertility outcomes (187 patients) [28, 29, 32, 33, 35-37, 219 
39, 42], 49 pregnancies and 35 live births were reported; 43% (44/103) patients who were 220 
reported to have been attempting to conceive after achieving pathological complete response 221 
were successful, the majority with fertility treatment. Overall, 35/49 (71%) of pregnancies 222 
resulted in live births. 223 
Intrauterine Progestin: Analysis of the two studies involving IUD progestin treatment 224 
involved 22 patients with grade 1 Stage I EC; overall, 15/22 (68%, 95% CI 45-86%) achieved 225 
pathological complete response with levonorgestrel or progesterone IUD treatment for six 226 
months or longer. Response rates were similar across both studies:  7/11 (64%) in the Montz 227 
study and 8/11 (73%) in the QCGC series. No relapses or progressions were reported after 6-228 
71 months of follow-up. Fertility outcomes were not reported. 229 
Sensitivity analyses 230 
When selection criteria were extended to include studies involving three or more eligible 231 
patients in either treatment arm requiring at least three or more months of treatment, the 232 
resulting meta-analysis involved 34 studies and 17 patients from the QCGC case series (470 233 
patients, 239 with CAH, 231with grade 1 Stage I EC) [15, 27-42, 46, 48-63]. Among patients 234 
treated with oral progestins, 118/194 (61%, 95% CI 54 – 68%) patients with CAH and 235 
128/194 (66%, 95% CI 59–73%) patients with EC achieved pathological complete response. 236 
Among patients treated with intrauterine progestins, 38/45 (84%, 95% CI 71–94%) patients 237 
with CAH and 17/37 (46%, 95% CI 29–63%) patients with EC achieved pathological 238 
complete response. Table 2 summarises the results of both analyses. 239 
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Risk of publication bias 240 
The funnel plot to assess publication bias showed reasonable symmetry around the overall 241 
estimated response rate, as did the funnel plot from the sensitivity analysis involving 242 
broadened selection criteria (not shown). This suggests that the risk of publication bias is low. 243 
A formal test for publication bias based on p-values could not be performed, due to lack of 244 
comparative arm in individual studies from which to obtain p-values [64]. 245 
 246 
DISCUSSION 247 
In the absence of data from randomised controlled trials, this meta-analysis provides evidence 248 
to counsel patients about likely benefit, as well as risk, of non-response and relapse. The 249 
estimated pathological complete response rate is 74% for CAH and 72% for grade 1 Stage I 250 
EC following six months or longer of oral progestin treatment, and 68% following 251 
progesterone IUD treatment. More recent studies tended to show higher response rates, 252 
possibly reflecting improving standards of treatment over time. 253 
Previous reviews on the subject included studies with very low numbers of patients. Some 254 
reviews did not control for study quality by failing to pose restrictions on treatment duration 255 
[43-45, 65], by not requiring radiological staging for EC [44, 45], or not limiting outcome to 256 
pathological complete response [43-45]. Our analysis addressed these concerns by limiting 257 
inclusion to studies involving at least ten patients in either treatment arm and requiring a 258 
period of treatment of at least six months, allowing reasonable time for complete response. 259 
We predefined diagnosis and outcome criteria in an effort to minimise heterogeneity between 260 
studies. However, the sensitivity analysis allowed assessment of the impact of these 261 
somewhat arbitrary decisions. 262 
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Oral progestin treatment was effective in achieving pathological complete response in at least 263 
two in three patients across all included studies, and for patients with EC intrauterine 264 
progestin appeared similarly effective. However, of patients that responded, one in five 265 
subsequently relapsed at a mean follow-up of two years following the end of progestin 266 
treatment. A small proportion of patients worsened from CAH to Stage I EC on oral 267 
progestins. When analysis was extended to include studies with smaller numbers of eligible 268 
patients or shorter treatment period, the estimates obtained for response to both oral (CAH 269 
and EC patients) and intrauterine progestins (EC patients) were lower, due to low response 270 
rates observed in several of the smaller studies. The transparency of study procedures in 271 
several of these smaller studies was less well developed compared to the larger studies 272 
included in our main analyses, indicating possible methodological problems. This supports 273 
our approach in limiting analysis to larger, higher-quality studies. 274 
Results from the extended analysis suggest that up to 84% of patients with CAH may achieve 275 
a pathological complete response with intrauterine progestin treatment, a higher response rate 276 
than that obtained with oral progestin treatment (61%). This finding is comparable to a 90% 277 
regression rate to intrauterine progestin in CAH patients reported by Gallos and colleagues, a 278 
review that included both partial and complete response as the outcome variable [43]. 279 
Intrauterine progestin may be a more effective option for conservative treatment of patients 280 
with CAH, and may avoid the systemic side-effects commonly reported under oral progestin 281 
treatment such as weight gain; however, further studies are required to compare the 282 
effectiveness and adverse effect profiles of these two routes of progestin administration. 283 
Among patients with CAH treated with oral progestin, the estimated pathological complete 284 
response rate from our main analysis is better than the regression rate (including both 285 
complete and partial response) reported in the systematic review by Gallos and colleagues 286 
(74% vs. 69%). This may be due to the fact that our analysis includes only CAH patients 287 
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treated for six months or longer, whereas Gallos et al. did not pose any treatment duration 288 
criteria in their analysis. Our findings suggest that treatment duration of at least six months 289 
for CAH patients should be recommended to obtain optimal response rates. 290 
Among patients with grade 1 Stage 1 EC, we obtained an estimated pathological complete 291 
response rate to oral progestin slightly lower than that reported in a previous review of nine 292 
small retrospective case series (72% vs. 79%) [44] and a recent review of eleven small 293 
studies (72% vs 81%) [66]. Neither of these reviews, however, limited the outcome variable 294 
to complete response, nor excluded patients that had additional treatment apart from systemic 295 
progestin, which may explain the higher response rate reported in these reviews.While the 296 
majority of patients in our analysis achieved a pathological complete response to oral 297 
progestin treatment, relapses and disease progression were observed. Overall, 6/219 (2.7%) 298 
patients progressed from CAH to EC, and 32/159 (20%) of patients who initially achieved a 299 
pathological complete response subsequently relapsed at a mean of two years following the 300 
end of treatment. Some case reports not included in this analysis due to small sample size 301 
even document a patient progressing from Stage I to Stage IV EC under progestin treatment 302 
[67], and development of EC one and four years after patients were treated with IUD-303 
delivered progestin for non-malignant causes [68, 69]. The data on risk of persistent or 304 
progressive disease or relapse needs to be discussed with patients considering progestin 305 
treatment. 306 
Insufficient reported information was available from included studies about clinical 307 
characteristics or treatment details of those patients who relapsed to allow analysis of factors 308 
associated with relapse. Smaller doses of oral progestin treatment [32, 37], obesity [70], and a 309 
history of anovulation or sporadic ovulation [32, 37] have been suggested by some authors as 310 
factors to consider. A study by Penner and colleagues did not find a difference in response 311 
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rate depending on patients age (<35 years or 35-48 years); however, there was a trend for 312 
patients with BMI <35 to have higher response rates (p<0.10) [71]. There is insufficient 313 
reported data from studies included in our analysis to assess trends with increasing age. Of 314 
patients included in our analysis who relapsed, three of six received a second course of oral 315 
progestins and achieved another pathological complete response. Thus, further conservative 316 
treatment may still be used for patients who relapse. 317 
Limitations  318 
The present analysis is limited by the observational study design and small sample sizes of 319 
included studies, which used different drugs, dosages, regimens, and follow-up durations. 320 
There is also limited information on patients clinical and demographic characteristics, thus 321 
prohibiting assessment of factors associated with response or relapse. No randomised 322 
controlled trials were available. Given the complex results reported in this meta-analysis and 323 
the lack of evidence for factors associated with response to oral or intrauterine progestin 324 
treatment, further prospective studies are needed, which should collect detailed demographic 325 
and clinical data. Two non-randomised open label Phase II clinical trials are currently 326 
underway to examine the efficacy of levonorgestrel-releasing (LNG) IUD in patients with 327 
endometrial hyperplasia (including hyperplasia with atypia) or grade 1 endometrioid 328 
endometrial cancer (ClinicalTrials.gov Identifier: NCT01234818, NCT00788671) [72]. A 329 
difficulty with conducting randomised trials directly comparing conservative treatment with 330 
the standard of definitive surgery, is the ethical dilemma posed by allocating patients to a 331 
treatment associated with a significant risk of nonresponse. A select group of patients who 332 
are unsuitable for a hysterectomy (patients who still desire fertility, patients unfit for major 333 
surgery for medical reasons) are suitable candidates for conservative treatment. Randomised 334 
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trials on the efficacy of oral and IUD-delivered treatment are urgently warranted and will 335 
require close supervision of experienced gynaecological oncologists. 336 
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Figure 1: Study selection and exclusion process 547 






Table 1:  Characteristics of studies included in the systematic review and meta-analysis 552 

































































































































































































































Table 2: Summary proportion of patients with pathological complete response  555 
         Response rate (95% CI)       
Primary analysis  Extended analysis 
Oral  IUD  Oral  IUD 
CAH  74% (65 ‐ 81%)  ‐  ‐  61% (54 ‐ 68%)  84% (71 ‐ 94%) 
EC  72% (62 ‐ 80%)  68% (45 ‐ 86%)  ‐  66% (59 ‐ 73%)  46% (29 ‐ 63%) 
 556 
Abbreviations CAH:complex atypical endometrial hyperplasia; EC: endometrial adenocarcinoma; 557 
IUD: intrauterine device  558 
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Figure 2: Pathological complete response to oral and intra-uterine device delivered progestin 559 
treatment (Weighted mean and exact binomial 95% confidence interval)  560 
Abbreviations CAH: complex atypical endometrial hyperplasia; EC: endometrioid 561 
adenocarcinoma; IUD: intra-uterine device 562 
